Literature DB >> 23134983

Ingenol mebutate: induced cell death patterns in normal and cancer epithelial cells.

Martin Stahlhut1, Malene Bertelsen, Maria Hoyer-Hansen, Nannette Svendsen, Andre H Eriksson, Janet M Lord, Dagmar Scheel-Toellner, Stephen P Young, John R Zibert.   

Abstract

We investigated the proposed necrotic mechanism of ingenol mebutate, a natural compound with anti-cancer properties in human keratinocytes, the human squamous cell carcinoma cell line HSC-5, and HeLa cervix carcinoma cells. Topical application of a clinical dose of ingenol mebutate 0.05% (1.15 mM) gel to human reconstituted full-thickness skin equivalents strongly reduced epidermal, but not dermal viability. Ingenol mebutate showed cytotoxic potency between 200-300 M on normal and cancer cells. When keratinocytes were induced to differentiate, they became significantly less sensitive to ingenol mebutate and half-maximal induction of cell death required more than 300 M ingenol mebutate. Cytotoxic concentrations of ingenol mebutate caused rupture of the mitochondrial network within minutes paralleled by cytosolic calcium release in all cells. Subsequently, plasma membrane integrity was lost as seen by propidium uptake into the cells. This was in sharp contrast to lysis of cells with low concentrations of the detergent Triton X-100 that permeabilized the plasma membrane within minutes without affecting organelle morphology. Buffering of intracellular calcium and inhibition of the mitochondrial permeability transition pore reduced the cytotoxic effect of ingenol mebutate in cancer cells, but not in normal keratinocytes. However, these inhibitors could not prevent cell death subsequent to prolonged incubation. Our findings reveal that ingenol mebutate does not mediate cytotoxicity by a simple lytic, necrotic mechanism, but activates distinct processes involving multiple cell organelles in a cell-type and differentiation-dependent manner. These data improve our understanding of ingenol mebutate-target cell interactions and offer new insights relevant to the removal of aberrant cells in human skin.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23134983

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN: 1545-9616            Impact factor:   2.114


  15 in total

1.  [Successful treatment of Bowen disease with ingenol mebutate].

Authors:  S A Braun; B Homey; P A Gerber
Journal:  Hautarzt       Date:  2014-10       Impact factor: 0.751

2.  Ingenol mebutate treatment in keloids.

Authors:  Bruna De Felice; Marco Guida; Luigi Boccia; Massimo Nacca
Journal:  BMC Res Notes       Date:  2015-09-22

3.  Ingenol mebutate: a succinct review of a succinct therapy.

Authors:  David Rhys Alchin
Journal:  Dermatol Ther (Heidelb)       Date:  2014-08-27

4.  Assessment of local skin reactions with a sequential regimen of cryosurgery followed by ingenol mebutate gel, 0.015%, in patients with actinic keratosis.

Authors:  Gary Goldenberg; Brian Berman
Journal:  Clin Cosmet Investig Dermatol       Date:  2014-12-16

5.  IL-1 Contributes to the Anti-Cancer Efficacy of Ingenol Mebutate.

Authors:  Thuy T Le; Kresten Skak; Kate Schroder; Wayne A Schroder; Glen M Boyle; Carly J Pierce; Andreas Suhrbier
Journal:  PLoS One       Date:  2016-04-21       Impact factor: 3.240

6.  Repeated Treatments with Ingenol Mebutate Prevents Progression of UV-Induced Photodamage in Hairless Mice.

Authors:  Andrés Már Erlendsson; Daniel Thaysen-Petersen; Christiane Bay; Andreas Hald; Kresten Skak; John Robert Zibert; Uwe Paasch; Hans Christian Wulf; Merete Haedersdal
Journal:  PLoS One       Date:  2016-09-16       Impact factor: 3.240

7.  Chemical Proteomics Identifies SLC25A20 as a Functional Target of the Ingenol Class of Actinic Keratosis Drugs.

Authors:  Christopher G Parker; Christian A Kuttruff; Andrea Galmozzi; Lars Jørgensen; Chien-Hung Yeh; Daniel J Hermanson; Yujia Wang; Marta Artola; Steven J McKerrall; Christopher M Josyln; Bjarne Nørremark; Georg Dünstl; Jakob Felding; Enrique Saez; Phil S Baran; Benjamin F Cravatt
Journal:  ACS Cent Sci       Date:  2017-12-06       Impact factor: 14.553

8.  Recurrent in situ melanoma successfully treated with ingenol mebutate.

Authors:  Marion Mansuy; Nazli Nikkels-Tassoudji; Jorge E Arrese; Andree Rorive; Arjen F Nikkels
Journal:  Dermatol Ther (Heidelb)       Date:  2014-04-02

9.  Ingenol Disoxate: A Novel 4-Isoxazolecarboxylate Ester of Ingenol with Improved Properties for Treatment of Actinic Keratosis and Other Non-Melanoma Skin Cancers.

Authors:  Malene Bertelsen; Martin Stahlhut; Gunnar Grue-Sørensen; Xifu Liang; Gitte Bach Christensen; Kresten Skak; Karen Margrethe Engell; Thomas Högberg
Journal:  Dermatol Ther (Heidelb)       Date:  2016-08-08

10.  Tumor-Preferential Induction of Immune Responses and Epidermal Cell Death in Actinic Keratoses by Ingenol Mebutate.

Authors:  Steffen Emmert; Holger A Haenssle; John R Zibert; Margarete Schön; Andreas Hald; Maria H Hansen; Thomas Litman; Michael P Schön
Journal:  PLoS One       Date:  2016-09-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.